ING Groep NV raised its stake in shares of Viveve Medical Inc (NASDAQ:VIVE) by 7.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 350,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. ING Groep NV’s holdings in Viveve Medical were worth $1,740,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VIVE. Schwab Charles Investment Management Inc. purchased a new position in shares of Viveve Medical during the 2nd quarter valued at about $189,000. Rhumbline Advisers purchased a new position in shares of Viveve Medical in the 2nd quarter valued at about $110,000. Bank of New York Mellon Corp purchased a new position in shares of Viveve Medical in the 2nd quarter valued at about $310,000. JPMorgan Chase & Co. purchased a new position in shares of Viveve Medical in the 2nd quarter valued at about $151,000. Finally, Teachers Advisors LLC purchased a new position in shares of Viveve Medical in the 2nd quarter valued at about $196,000. Institutional investors and hedge funds own 66.89% of the company’s stock.

Shares of Viveve Medical Inc (VIVE) opened at $4.43 on Monday. Viveve Medical Inc has a 52 week low of $3.30 and a 52 week high of $11.16. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. The company has a market capitalization of $86.06, a P/E ratio of -2.05 and a beta of -0.79.

Several equities analysts recently weighed in on VIVE shares. ValuEngine lowered Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Mizuho restated a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research note on Friday, January 5th. Cowen set a $11.00 price target on Viveve Medical and gave the company a “buy” rating in a research note on Monday, October 23rd. Northland Securities started coverage on Viveve Medical in a research note on Friday, January 5th. They issued an “outperform” rating and a $8.00 price target for the company. Finally, Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Viveve Medical in a research note on Thursday, January 4th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.00.

WARNING: This article was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://theolympiareport.com/2018/02/12/ing-groep-nv-buys-25000-shares-of-viveve-medical-inc-vive.html.

Viveve Medical Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Want to see what other hedge funds are holding VIVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viveve Medical Inc (NASDAQ:VIVE).

Institutional Ownership by Quarter for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.